NAMS vs NRIX Stock Comparison

NRIX currently leads NAMS in this stock comparison, with AIQ scores of 65 vs 41. The clearest difference is value, while NAMS has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 24 points
NAMS
Healthcare
vs
NRIX
Healthcare
NAMS
NewAmsterdam Pharma Company N.V.
Price
$20.14
Day move
+0.85%
AIQ Score
41/100
Best edge
Risk Resilience
Sector
Healthcare
NRIX
Nurix Therapeutics, Inc.
Leads
Price
$15.48
Day move
-0.77%
AIQ Score
65/100
Best edge
Value
Sector
Healthcare

What is the main difference between NAMS and NRIX?

NRIX leads the current stock comparison as Nurix Therapeutics, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

NewAmsterdam Pharma Company N.V. vs Nurix Therapeutics, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 6/10

NRIX leads

NRIX leads by 24 AIQ points, primarily on Value and Momentum, but the lead has narrowed from 44 points over 30 sessions. Wall Street currently favors NAMS on target upside.

Fragile: 3 of 6 evidence groups support NRIX, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Weakening
NAMS

NewAmsterdam Pharma Company N.V.

AIQ Score
41/100
AIQ Edge Score
2/10
NRIX

Nurix Therapeutics, Inc.

Leads
AIQ Score
65/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors NRIX over NAMS, 65 versus 41 as of Nov 15, 2026. NRIX's advantage is driven primarily by stronger value and momentum, while NAMS holds the stronger risk resilience profile. NRIX also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors NAMS. 3 of 6 covered evidence groups favor NRIX today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. NRIX lead: Weakening — the AIQ differential moved from 44 to 24 points over 30 sessions.

Compare NewAmsterdam Pharma Company N.V. and Nurix Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

NAMS
+94.6%
NRIX
+30.2%

Price return comparison

Growth of $10,000, price only

NAMS $19,459 · NRIX $13,019

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare NAMS and NRIX against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

NAMS advantage
0
NRIX advantage
  • Value42 vs 94
    NRIX +52
  • Momentum22 vs 50
    NRIX +28
  • Quality58 vs 78
    NRIX +20
  • Risk Resilience48 vs 40
    NAMS +8

3 of 6 evidence groups favor NRIX. NRIX’s edge is concentrated in value and momentum; NAMS keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

NAMS0 AIQ

Largest factor move: Value +2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 6 active signals are unchanged.

NRIX0 AIQ

Largest factor move: Value +1, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 5 active signals are unchanged.

NRIX's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — NAMS and NRIX both carry a full feed there.

The central trade-off

NRIX (Nurix Therapeutics, Inc.): the stronger current systematic profile, led by value and momentum.

NAMS (NewAmsterdam Pharma Company N.V.): the counter-case, on risk resilience, technicals, analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

NRIX

NRIX on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

NRIX

NRIX on combined revenue and EPS growth.

Value

NRIX

NRIX on the peer-relative Value factor, by 52 points.

Momentum

NRIX

NRIX on the Momentum factor, by 28 points.

Lower downside

NAMS

NAMS on Risk Resilience, by 8 points.

Analyst upside

NAMS

NAMS on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors NRIX, analyst targets favor NAMS. That disagreement is the most useful thing on this page.

MeasureNAMSNRIXNote
Implied upside to target+202.9%+117.2%NAMS has more room
Target dispersion0%+62.5%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1614Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor NRIX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreNRIX41 vs 65
FundamentalsNRIXon balancerevenue growth 4.2% vs 73.4%; EPS growth 73.1% vs 7.1%; TTM ROE -2.8% vs 56.8%; gross margin 97.8% vs 86.5%; operating margin -9% vs 41.3% — NRIX takes 3 of 5 decided legs, not all of them
ValuationNRIXValue 42 vs 94
TechnicalsNAMSPrice vs 50-day -6.4% vs -33.5%; vs 200-day -30.9% vs -23.1%
Risk ResilienceNAMSRisk Resilience 48 vs 40
Analyst expectationsNAMSTarget upside 202.9% vs 117.2%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of NAMS and NRIX and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is wide at 24 points. (supports the conclusion holding)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has swung materially session to session. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on NRIX.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

NRIX lead: Weakening — the AIQ differential moved from 44 to 24 points over 30 sessions.

May 27NAMS leads above the line · NRIX leads belowNov 13
Today
NRIX +24
41 vs 65
7 sessions ago
NRIX +35
39 vs 74
30 sessions ago
NRIX +44
34 vs 78
90 sessions ago
NRIX +16
40 vs 56

The lead changed hands 3 times in this window, most recently on Jul 20 when NRIX moved ahead of NAMS.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

NAMSConflicted

1 bullish / 3 bearish / 2 neutral, conflicted

Only NAMS

  • Death Cross Active — bearish, trend, long horizon (35.44%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
NRIXConflicted

2 bullish / 1 bearish / 2 neutral, conflicted

Only NRIX

  • Golden Cross Active — bullish, trend, long horizon (15.60%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Keltner Channel Breakdown — bearish, volatility, short horizon
  • RSI Oversold — bullish, momentum, short horizon

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

NRIX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

NAMSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.85%, AIQ 0 points).

NRIXNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.77%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1NAMS closes the Value gap — currently 52 points behind, the largest single contributor to NRIX's edge.
  2. 2NAMS's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3NRIX's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 20 points over 30 sessions, and a further 24-point move would eliminate NRIX's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

NRIX leads on balance
MetricNAMSNRIX
Revenue growth (YoY)4.2%73.4%
EPS growth (YoY)73.1%7.1%
Gross margin97.8%86.5%
Operating margin-9%41.3%
Return on equity (TTM)-2.8%56.8%
Debt to equity00.07

Performance

Split across windows
MetricNAMSNRIX
1 week (5 sessions)6.6%1.2%
1 month (20 sessions)1.6%-36.6%
3 months (63 sessions)-25.1%-43%
6 months (126 sessions)-43.2%-2.4%
Year to date-42.6%-18.4%
1 year (252 sessions)-47.4%27.2%

Technicals

NAMS has the stronger structure
MetricNAMSNRIX
RSI (14)47.326.8
ADX (14)16.735.9
Price vs 50-day-6.4%-33.5%
Price vs 200-day-30.9%-23.1%
Volatility (1M, annualized)69.8%145.5%

Risk

NAMS is the more resilient
MetricNAMSNRIX
Beta1.431.06
Sharpe ratio-0.910.64
Sortino ratio-1.250.87
Max drawdown-54.4%-46.6%
Current drawdown-51.4%-44.3%
Annualized volatility53.8%67.3%
Value at risk (95%)-5.2%-4.8%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, NAMS or NRIX?

On the Algovestiq AIQ Score, NRIX is the stronger of the two as of Nov 15, 2026, scoring 65 against NAMS's 41. The edge comes from value and momentum. NAMS is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is NAMS or NRIX the better buy right now?

NRIX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor NRIX over NAMS?

The composite weights Quality, Value, Momentum and Risk Resilience. NRIX leads Value by 52 points; NRIX leads Momentum by 28 points; NRIX leads Quality by 20 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, NAMS or NRIX?

Analyst price targets imply +202.9% upside for NAMS and +117.2% for NRIX, so the Street currently favors NAMS. That points the opposite way to the AIQ Score, which favors NRIX. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, NAMS or NRIX?

NRIX is the better-valued of the two on the peer-relative Value factor. NRIX on the peer-relative Value factor, by 52 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, NAMS or NRIX?

NRIX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, NAMS or NRIX?

NRIX on the Momentum factor, by 28 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, NAMS or NRIX?

NAMS is the more resilient of the two, so the other name carries the higher downside risk. NAMS on Risk Resilience, by 8 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is NAMS more profitable than NRIX?

The profitability evidence is mixed: gross margin 97.8% vs 86.5%; operating margin -9% vs 41.3%; ttm roe -2.8% vs 56.8%. NAMS leads on one measure and NRIX on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is NRIX's lead over NAMS getting stronger or weaker?

NRIX lead: Weakening — the AIQ differential moved from 44 to 24 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 3 times in that window, most recently on 2026-07-20, when NRIX moved ahead of NAMS.

What would change the NAMS vs NRIX verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: NAMS closes the Value gap — currently 52 points behind, the largest single contributor to NRIX's edge; NAMS's Death Cross Active resolves — a bearish trend rule currently active against it; NRIX's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 20 points over 30 sessions, and a further 24-point move would eliminate NRIX's advantage entirely.

What do the current signals say about NAMS and NRIX?

NAMS: 1 bullish / 3 bearish / 2 neutral, conflicted. NRIX: 2 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on NAMS is Death Cross Active (bearish, long horizon). On NRIX it is Golden Cross Active (bullish, long horizon).

Compare NAMS and NRIX with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.